231 related articles for article (PubMed ID: 15781984)
1. Estrogen receptors and their downstream targets in cancer.
Ikeda K; Inoue S
Arch Histol Cytol; 2004 Dec; 67(5):435-42. PubMed ID: 15781984
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of estrogen action: selective ligands and receptor pharmacology.
Katzenellenbogen BS; Choi I; Delage-Mourroux R; Ediger TR; Martini PG; Montano M; Sun J; Weis K; Katzenellenbogen JA
J Steroid Biochem Mol Biol; 2000 Nov; 74(5):279-85. PubMed ID: 11162936
[TBL] [Abstract][Full Text] [Related]
3. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
4. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells.
Marsaud V; Gougelet A; Maillard S; Renoir JM
Mol Endocrinol; 2003 Oct; 17(10):2013-27. PubMed ID: 12855746
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells.
Zhao C; Matthews J; Tujague M; Wan J; Ström A; Toresson G; Lam EW; Cheng G; Gustafsson JA; Dahlman-Wright K
Cancer Res; 2007 Apr; 67(8):3955-62. PubMed ID: 17440111
[TBL] [Abstract][Full Text] [Related]
6. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
7. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth.
Urano T; Saito T; Tsukui T; Fujita M; Hosoi T; Muramatsu M; Ouchi Y; Inoue S
Nature; 2002 Jun; 417(6891):871-5. PubMed ID: 12075357
[TBL] [Abstract][Full Text] [Related]
8. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta.
Buteau-Lozano H; Ancelin M; Lardeux B; Milanini J; Perrot-Applanat M
Cancer Res; 2002 Sep; 62(17):4977-84. PubMed ID: 12208749
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells.
Gougelet A; Bouclier C; Marsaud V; Maillard S; Mueller SO; Korach KS; Renoir JM
J Steroid Biochem Mol Biol; 2005 Feb; 94(1-3):71-81. PubMed ID: 15862952
[TBL] [Abstract][Full Text] [Related]
10. The estrogen receptor-interacting protein HPIP increases estrogen-responsive gene expression through activation of MAPK and AKT.
Wang X; Yang Z; Zhang H; Ding L; Li X; Zhu C; Zheng Y; Ye Q
Biochim Biophys Acta; 2008 Jun; 1783(6):1220-8. PubMed ID: 18302941
[TBL] [Abstract][Full Text] [Related]
11. The AF-2 cofactor binding region is key for the selective SUMOylation of estrogen receptor alpha by antiestrogens.
Vallet A; El Ezzy M; Diennet M; Haidar S; Bouvier M; Mader S
J Biol Chem; 2023 Jan; 299(1):102757. PubMed ID: 36460099
[TBL] [Abstract][Full Text] [Related]
12. Involvement of suppressor for Gal 1 in the ubiquitin/proteasome-mediated degradation of estrogen receptors.
Masuyama H; Hiramatsu Y
J Biol Chem; 2004 Mar; 279(13):12020-6. PubMed ID: 14702340
[TBL] [Abstract][Full Text] [Related]
13. The GPER1/SPOP axis mediates ubiquitination-dependent degradation of ERα to inhibit the growth of breast cancer induced by oestrogen.
Zhang N; Sun P; Xu Y; Li H; Liu H; Wang L; Cao Y; Zhou K; TinghuaiWang
Cancer Lett; 2021 Feb; 498():54-69. PubMed ID: 33069770
[TBL] [Abstract][Full Text] [Related]
14. Antiestrogens: structure-activity relationships and use in breast cancer treatment.
Traboulsi T; El Ezzy M; Gleason JL; Mader S
J Mol Endocrinol; 2017 Jan; 58(1):R15-R31. PubMed ID: 27729460
[TBL] [Abstract][Full Text] [Related]
15. Generation of stable reporter breast cancer cell lines for the identification of ER subtype selective ligands.
Shanle EK; Hawse JR; Xu W
Biochem Pharmacol; 2011 Dec; 82(12):1940-9. PubMed ID: 21924251
[TBL] [Abstract][Full Text] [Related]
16. Selectively targeting estrogen receptors for cancer treatment.
Shanle EK; Xu W
Adv Drug Deliv Rev; 2010 Oct; 62(13):1265-76. PubMed ID: 20708050
[TBL] [Abstract][Full Text] [Related]
17. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex.
Chen B; Gajdos C; Dardes R; Kidwai N; Johnston SR; Dowsett M; Jordan VC
Int J Oncol; 2005 Aug; 27(2):327-35. PubMed ID: 16010412
[TBL] [Abstract][Full Text] [Related]
18. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
Reiter R; Oh AS; Wellstein A; Riegel AT
Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
[TBL] [Abstract][Full Text] [Related]
19. CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha.
Fan M; Park A; Nephew KP
Mol Endocrinol; 2005 Dec; 19(12):2901-14. PubMed ID: 16037132
[TBL] [Abstract][Full Text] [Related]
20. Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation.
Power KA; Thompson LU
Breast Cancer Res Treat; 2003 Oct; 81(3):209-21. PubMed ID: 14620916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
